Cite
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis
MLA
Moritz Müller, et al. “Benefit of Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: A Tri-Center Propensity Score Analysis.” Therapeutic Advances in Medical Oncology, vol. 13, Sept. 2021. EBSCOhost, https://doi.org/10.1177/17588359211039930.
APA
Moritz Müller, Florian Posch, Dominik Kiem, Dominik Barth, Lena Horvath, Michael Stotz, Renate Schaberl-Moser, Martin Pichler, Richard Greil, Philipp J. Jost, Andreas Seeber, Arno Amann, Konstantin Schlick, Armin Gerger, & Jakob M. Riedl. (2021). Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis. Therapeutic Advances in Medical Oncology, 13. https://doi.org/10.1177/17588359211039930
Chicago
Moritz Müller, Florian Posch, Dominik Kiem, Dominik Barth, Lena Horvath, Michael Stotz, Renate Schaberl-Moser, et al. 2021. “Benefit of Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: A Tri-Center Propensity Score Analysis.” Therapeutic Advances in Medical Oncology 13 (September). doi:10.1177/17588359211039930.